CoChat

Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics

Goldstein, Burton J., Goodnick, Paul J · 1998 · Journal of Psychopharmacology

The DOI matches its Crossref record; 282 of the 283 references it cites were found in a registry or an index.

Abstract

The clinical use of tricyclic antidepressants (TCAs) is often complicated by toxicity and safety problems due to their effects on multiple mechanisms of action, many of which are unnecessary for therapeutic effect. The development of the selective serotonin reuptake inhibitors (SSRIs), with their selective mode of action, has resulted in a class of antidepressant drugs possessing an improved side-effect profile, while retaining good clinical efficacy. Their introduction into clinical practice has led to enhanced patient compliance with antidepressant therapy and the ability to maintain treatment over longer periods of time at an adequate therapeutic dose. Although, as a result of their selective action, side-effects associated with SSRI therapy are minimised, distinct variations between individual SSRIs in terms of their tolerability profiles have been observed. The wealth of clinical data now available has revealed differences in their potential to cause psychiatric and neurological side-effects, dermatological reactions, anticholinergic side-effects, changes in body weight, sexual dysfunction, cognitive impairment, discontinuation reactions and drug-drug interactions. Patients who suffer from concomitant depression and physical illness may experience different tolerability profiles, in addition to the greater likelihood that they will be receiving concomitant medications with the potential for pharmacokinetic drug-drug interactions with coadministered SSRI therapy. In addition, the safety margin of SSRIs in overdose may vary within the group. Knowledge of the differences that exist among the SSRIs in respect of tolerability and safety will aid physicians in the selection of the most beneficial treatment strategy for their patients. A successful clinical outcome leads to a reduced economic burden for the patient, their family and the healthcare services. Thus, pharmacoeconomic considerations are also important in choosing antidepressant therapy. The SSRIs, despite relatively higher prescription costs, have been demonstrated to be a more cost-effective option than the TCAs. Furthermore, there is evidence that the emerging clinical differences between SSRIs may translate into significantly different economic outcomes within the group.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881198012003041

Cites

282 of 282 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 282 references

Research works printed but not linked: 153

  1. 1996, Austr Adverse Drug Reactions Bull, 15, 3
  2. New Research Abstracts American Psychiatric Association Annual Meeting
  3. 1983, J Affect Disord, 51, 15
  4. 1994, Review of the literature. Encéphale, 20, 65
  5. 1993, JAMA, 269, 869
  6. 1994, J Clin Psychiatry, 55, 394
  7. 1998, J Affect Disord, 46, 151
  8. 1996, Aus NZ J Psychiatry, 30, 702
  9. 1991, Am J Psychiatry, 148, 274
  10. 1993, J Clin Psychiatry, 54, 115
  11. 1989, Acta Psychiatr Scand, 80, 102
  12. 1993, J Clin Psychopharmacol, 13, 312
  13. 1996, J Clin Psychiatry, 57, 93
  14. 1995, J Clin Psychiatry, 56, 229
  15. 1996, J Clin Psychiatry, 57, 93
  16. 1993, Clin Pharmacol Ther, 1, 84
  17. 1994, Curr Affective Illness, 13, 14
  18. 1996, Eur Neuropsychopharmacol, 6, 122
  19. 1993, J Clin Psychiatry, 54, 146
  20. 1996, Encephale, 22, 221
  21. Boyer W.F., Feighner J.P. (1991) Pharmacokinetics and drug interactions. In Feighner J P, Boyer W F (eds), Perspectives in psychiatry, vol. 1. Selective serotonin reuptake inhibitors. John Wiley & Sons, Chichester, pp. 81-88.
  22. Poster presented at the 148th Annual Meeting of the American Psychiatric Association
  23. 1995, J Clin Psychiatry, 56, 30
  24. 1998, Praxis, 87, 345
  25. 1991, J Clin Psychiatry, 52, 174
  26. Bunney W.E. (1978) Psychopharmacology of the switch process in affective illness. In Lipton M A, DiMascio A, Kellam K F (eds), Psychopharmacology: a generation of progress. Raven Press, New York, pp.1249-1259.
  27. 1994, Citalopram product monograph
  28. 1992, J Clin Psychiatry, 53, 272
  29. 1992, J Clin Psychiatry, 53, 278
  30. 1994, Neuropsychopharmacology, 10, 222S
  31. 1993, Curr Prob, 19, 1
  32. 1988, Br J Psychiatry, 3, 77
  33. 1996, Sexual pharmacology: drugs that affect sexual functioning
  34. 1994, J Clin Psychopharmacol, 14, 340
  35. 1996, Br J Psychiatry, 68, 164
  36. 1995, Am J Psychiatry, 152, 1253
  37. 1990, J Clin Psychiatry, 51, 385
  38. 1996, J Clin Psychopharmacol, 16, 37S
  39. 1997, Encephale, 23, 39
  40. 1993, Summary basis of approval for Paxil (paroxetine)
  41. 1991, J Clin Psychiatry, 52, 163
  42. 1993, Scand J Gastroenterology, 28, 40
  43. 1996, J Clin Psychiatry, 57, 53
  44. 1994, Neuropsychopharmacology, 10, 165S
  45. New Research Program Abstracts American Psychiatric Association Annual Meeting
  46. 1996, J Clin Psychiatry, 57, 23
  47. 1996, Psychopharmacol Bull, 32, 653
  48. 1994, Eur J Pharmacol, 46, 35
  49. 1991, West J Med, 155, 522
  50. 1993, JAMA, 270, 1860, 10.1001/jama.1993.03510150094038 · doi:10.1001/jama.1993.03510150094038
  51. 1993, Br J Clin Res, 4, 145
  52. 1997, Clin Pharmacokinet, 32, 43
  53. 1987, J Clin Psychopharmacol, 7, 329
  54. 1992, J Clin Psychiatry, 53, 401
  55. 1988, Psychopharmacol Bull, 24, 220
  56. 1992, Eur J Med, 1, 343
  57. 1990, J Clin Psychiatry, 51, 25
  58. 1990, J Clin Psychiatry, 51, 34
  59. 1990, J Clin Psychopharmacol, 10, 343
  60. 1991, J Clin Psychiatry, 52, 131
  61. 1997, J Clin Outcome Management, 4, 16
  62. 1993, Nord J Psychiatry, 47, 5
  63. 1992, J Clin Psychiatry, 53, 119
  64. 1981, Acta Psychiatr Scand, 63, 447
  65. 1996, Eur Neuropsychopharmacol, 6, 143
  66. 1995, J Med Assoc Thailand, 78, 53
  67. 1992, Vet Hum Toxicol, 34, 343
  68. 1996, Formulary, 31, 374
  69. 1994, J Clin Psychiatry, 55, 137
  70. 1992, J Clin Psychiatry, 53, 127
  71. 1994, Am J Geriatr Psychiatry, 2, 271
  72. 1992, Int Clin Psychopharmacol, 7, 101
  73. 1997, Clin Pharmacol Therap, 61, 178
  74. 1996, International Clin Psychopharmacol, 11, 31
  75. 1996, J Serotonin Res, 3, 75
  76. 1998, J Psychopharmacol, 12, 208
  77. 1995, J Serotonin Res, 3, 171
  78. New Research Program and Abstracts. Paper presented at the 148th Annual Meeting of the American Psychiatric Association
  79. 1996, Eur Neuropsychopharmacol, 6, 124
  80. 1987, Am J Psychiatry, 144, 16
  81. 1994, CNS Drugs, 2, 132
  82. 1995, Eur J Clin Res, 7, 287
  83. Poster presented at the 148th Annual Meeting of the American Psychiatric Association
  84. 1993, J Clin Psychopharmacol, 13, 175
  85. 1989, J Clin Psychiatry, 50, 339
  86. 1998, Br J Psychiatry, 183
  87. 1989, South African Med J, 82, 933
  88. 1996, Scotland. Br Med J, 313, 860
  89. 1995, J Clin Psychiatry, 56, 82
  90. 1988, J Clin Psychiatry, 49, 52
  91. 1990, J Clin Psychiatry, 51, 60
  92. 1995, J Clin Psychiatry, 56, 49
  93. 1996, Eur Neuropsychopharmacol, 6, 36
  94. Poster presented at the BAP/BNPA Summer Meeting
  95. Medical Economics Data (1997a) Prozac (fluoxetine hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 943-947.
  96. Medical Economics Data (1997b) Paxil (paroxetine hydrochloride) Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2681-2686.
  97. Medical Economics Data (1997c) Zoloft (sertraline hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2051-2053.
  98. Medical Economics Data (1997d) Effexor (venlafaxine hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co. Montvale, NJ, pp. 2825-2829. Medical Economics Data (1997e) Luvox (fluvoxamine maleate). Physicians desk reference (51st edn). Medical Economics Data Production Co. Montvale, NJ, pp. 2723-2726.
  99. New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association
  100. 1995, Am Fam Physician, 52, 1475
  101. 10.1002/(SICI)1099-1077(199609)11:5<365::AID-HUP815>3.0.CO;2-F · doi:10.1002/(sici)1099-1077(199609)11:5<365::aid-hup815>3.0.co;2-f
  102. Paper presented at the 148th Annual Meeting of the American Psychiatric Association
  103. 1993, Vet Hum Toxicol, 35, 341
  104. 1996, Eur Neuropsychopharmacol, 6, 35
  105. 1988, Neuropsychopharmacology, 27, 597602
  106. 1990, Arch Biochem Biophys, 276, 424432
  107. 1986, Br J Clin Pharmacol, 22, 97
  108. 1998, Clin Pharmacol Ther, 62, 334
  109. 1996, Int Clin Psychopharmacol, 11, 129
  110. 1994, Clin Pharmacol Ther, 54, 471
  111. 1992, Encephale, 18, 76
  112. Poster presented at 37th Annual New Clinical Drug Evaluation Unit Meeting
  113. 1995, Psychopharmacol Bull, 31, 327
  114. 1995, Clinical pharmacology of selective serotonin reuptake inhibitors
  115. Preskorn S.H., Janicak P.G., Davis J.M., Ayd F. Jr (1995) Advances in the pharmacotherapy of depressive disorders . In Janicak P G, Davis J M, Preskorn S H, Ayd FJ (eds), Principals and practice of psychopharmacotherapy. Williams & Wilkins, Baltimore, pp. 1-24.
  116. 1997, Psychopharmacol Bull, 33, 659
  117. 1998, Clin Pharmacol Therap, 63, 166
  118. 1996, J Clin Psychiatry, 57, 24
  119. 1996, J Clin Psychiatry, 57, 20
  120. 1994, J Clin Psychiatry, 55, 34
  121. 1998, Primary Psychiatry, 5, 40
  122. 1990, J Clin Psychiatry, 51, 9
  123. 1989, J Clin Psychiatry, 50, 12
  124. 1991, J Clin Psychiatry, 52, 491
  125. New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association
  126. New Research Abstracts American Psychiatric Association Annual Meeting
  127. 1995, Drugs, 4, 28
  128. 1994, Clin Ther, 16, 715
  129. 1993, J Clin Psychiatry Monograph, 11, 57
  130. 1991, Sleep Res, 20, 189
  131. 1997, J Clin Psychiatry, 58, 5
  132. 1994, J Clin Psychopharmacol, 14, 322
  133. 1996, Movement Disord, 11, 603
  134. 1997, Pharmacist, 22, 60
  135. 1997, Am J Man Care, 3, 125
  136. 1998, Eur J Clin Pharmacol, 53, 163
  137. 1988, Lancet, 2, 850
  138. New Research Program and Abstracts. Paper presented at the American Psychiatric Association 146th Annual Meeting
  139. 1998, Primary Psychiatry, 5, 28
  140. 1996, Am J Med, 101, 265
  141. 1993, J Clin Psychopharmacol, 13, 18S
  142. 1994, J Clin Psychopharmacol, 14, 163
  143. 1992, J Am Acad Child Adol Psychiatry, 31, 265
  144. 1998, Am J Psychiatry, 155, 344
  145. New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association
  146. 1983, Psychiatry Clin North Am, 5, 27
  147. 1996, J Clin Psychiatry, 57, 7
  148. 1994, Primary Psychiatry, 11, 22
  149. New Research Program and Abstracts American Psychiatry Association Annual Meeting
  150. 1991, Neuropsychopharmacology, 5, 43
  151. 1997, Psychopharmacol Bull, 33, 755
  152. 1987, Int J Obesity, 11, 191
  153. 1987, J Clin Psychopharmacol, 7, 254

Cited by

See all 171

Metadata

Authors
Goldstein, B. J., & Goodnick, P. J.
Affiliations
  • Health Services Research Center (Cyprus) (CY)
  • University of Miami (US)
Venue
Journal of Psychopharmacology
Published
1998-07
Volume
12
Issue
4_suppl
Pages
55-S87
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W1889727824
Cited by
171
References
283
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 12 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 10 · 2015: 6 · 2014: 7 · 2013: 7 · 2012: 7
FWCI
3.91
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
selective serotonin reuptake inhibitors, antidepressant tolerability, drug safety, pharmacoeconomics, tricyclic antidepressants, adverse drug reactions, drug-drug interactions, antidepressant overdose, cost-effectiveness, mood disorders, depression
MeSH terms
Humans, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. https://app.cochat.ai/papers/10.1177/0269881198012003041
The paper
Goldstein, B. J., & Goodnick, P. J. (1998). Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. Journal of Psychopharmacology. https://doi.org/10.1177/0269881198012003041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.